Substantial documents show that KRAS activation mutations widely existed in sundry malignant carcinoma including pancreatic, colon cancers and lung cancers [21, 22], and closely involved with undesirable progression and prognosis in clinic cancer therapy [23, 24]. The gene discussed is KRAS; the disease is lung carcinoma.